At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
Exenatide SRdrug
Likely dose
Exenatide SR 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Prospective, Randomized, Multicenter, Open-Label, Controlled Trial to Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation.
In Brief
A Phase 2 clinical trial evaluating Exenatide SR for Pre Diabetes. Completed, enrolled 9 participants across 1 site.
Detailed Summary
Researchers are trying to determine if an anti-diabetes medication, called Exenatide SR, is well tolerated in kidney transplant patients with elevated blood glucose levels, and if it's effective in preventing diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPre Diabetes
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartMay 2019
First PostedMay 2019
Primary CompletionOct 2021
TodayJul 2026
First PostedMay 23, 2019
Enrollment StartMay 9, 2019
Primary CompletionOct 18, 2021
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 7.1 years ago
Interventions
Exenatide SRdrug
Exenatide SR 2 mg subcutaneous (SQ) weekly